Autolus Therapeutics (AUTL) director granted options and RSUs in new equity awards

Rhea-AI Filing Summary

Autolus Therapeutics plc director Elisabeth Leiderman received new equity awards. She was granted options over 47,500 American Depositary Shares at an exercise price of $1.61 per share, vesting in twelve equal monthly installments starting on July 29, 2026, and 31,667 restricted share units that vest in one installment on June 29, 2027. Each RSU represents a right to receive one American Depositary Share, and each American Depositary Share is convertible into one Ordinary Share.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Leiderman Elisabeth

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Share Units	31,667	$0.00	--
Grant/Award	Share Option (Right to Buy)	47,500	$0.00	--

Holdings After Transaction: Restricted Share Units — 31,667 shares (Direct, null); Share Option (Right to Buy) — 47,500 shares (Direct, null)

Footnotes (1)

1. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share. The RSUs vest in one installment on June 29, 2027. Share options vest in twelve equal monthly installments commencing on July 29, 2026.

Key Figures

Share options granted: 47,500 options Option exercise price: $1.61 per share Option vesting schedule: 12 equal monthly installments +3 more

6 metrics

Share options granted 47,500 options Granted on June 29, 2026 to Elisabeth Leiderman

Option exercise price $1.61 per share Exercise price for 47,500 options

Option vesting schedule 12 equal monthly installments Vesting starts July 29, 2026

RSUs granted 31,667 RSUs Granted on June 29, 2026 to Elisabeth Leiderman

RSU vesting date June 29, 2027 Single-installment vesting date for 31,667 RSUs

ADS to Ordinary Share ratio 1:1 Each ADS convertible into one Ordinary Share

Key Terms

Share Option (Right to Buy), Restricted Share Units, American Depositary Shares, Ordinary Share, +1 more

5 terms

Share Option (Right to Buy) financial

"security_title: "Share Option (Right to Buy)""

Restricted Share Units financial

"security_title: "Restricted Share Units""

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

American Depositary Shares financial

"underlying_security_title: "American Depositary Shares""

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Ordinary Share financial

"convertible at any time ... into one Ordinary Share"

An ordinary share is a unit of ownership in a company that gives the holder a stake in its profits and usually the right to vote on key decisions. Think of it like a slice of a pizza where each slice entitles you to a portion of what’s left after bills are paid; value can rise or fall with the business and may pay dividends, so it matters to investors for income, growth and control.

vest financial

"The RSUs vest in one installment on June 29, 2027."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 04:15 PM Accepted by SEC EDGAR 07/01/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leiderman Elisabeth

(Last) (First) (Middle)

THE MEDIAWORKS, WHITE CITY

C/O AUTOLUS THERAPEUTICS PLC

(Street)

LONDON W12 7FP

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Autolus Therapeutics plc [ AUTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(1)	06/29/2026		A		31,667		(2)	(2)	American Depositary Shares	31,667	$0	31,667	D
Share Option (Right to Buy)	$1.61	06/29/2026		A		47,500		(3)	06/29/2036	American Depositary Shares	47,500	$0	47,500	D

Explanation of Responses:

1. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share.

2. The RSUs vest in one installment on June 29, 2027.

3. Share options vest in twelve equal monthly installments commencing on July 29, 2026.

	/s/ Elisabeth Leiderman	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Autolus Therapeutics (AUTL) report for Elisabeth Leiderman?

Autolus Therapeutics reported that director Elisabeth Leiderman received equity awards, not open-market trades. She was granted 47,500 share options and 31,667 restricted share units, both tied to American Depositary Shares and subject to multi-year vesting schedules.

How many stock options did Elisabeth Leiderman receive from Autolus Therapeutics (AUTL)?

Elisabeth Leiderman received 47,500 share options linked to American Depositary Shares. These options carry an exercise price of $1.61 per share and vest in twelve equal monthly installments, beginning on July 29, 2026, providing time-based, service-related compensation.

What are the terms of the restricted share units granted by Autolus Therapeutics (AUTL)?

Autolus Therapeutics granted 31,667 restricted share units to director Elisabeth Leiderman. Each RSU represents a contingent right to receive one American Depositary Share and vests in a single installment on June 29, 2027, creating a longer-term incentive aligned with future service.

Do the Autolus Therapeutics (AUTL) RSUs and options convert into Ordinary Shares?

Yes. Each restricted share unit represents one American Depositary Share, and each American Depositary Share is convertible at any time into one Ordinary Share. This structure links director equity awards directly to the company’s underlying Ordinary Shares.

Were there any stock sales or purchases by Elisabeth Leiderman in this Autolus Therapeutics (AUTL) Form 4?

No open-market stock sales or purchases were reported. The Form 4 shows grant or award acquisitions only: 47,500 options and 31,667 restricted share units, both as compensation-related equity awards rather than discretionary market transactions.